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Abstract
Background
Studies indicate suboptimal patient understanding of the capabilities, lifestyle
implications, and risks of LVAD therapy. This paper describes the development
methodology and pilot-testing of a decision aid for Left Ventricular Assist Device
(LVAD) placement, combining traditional needs-assessment with a novel usercentered approach.
Methods and Results
We developed the decision aid in line with the Ottawa Decision Support
Framework (ODSF) and the International Patient Decision Aids Standards
(IPDAS) for ensuring quality, patient-centered content. Structured interviews
were conducted with patients, caregivers, candidates for LVAD treatment, and
expert clinicians (n=71) to generate content based on patient values and
decisional needs, and providers’ perspectives on knowledge needs for informed
consent. The aid was alpha tested through cognitive interviews (n=5) and
acceptability tested with LVAD patients (n=10), candidates (n=10), and clinicians
(n=13). Patients, caregivers and clinicians reported they would recommend the
aid to patients considering treatment options for heart failure. Patients and
caregivers agreed that the decision aid is a balanced tool presenting risks and
benefits of LVAD treatment and generating discussion about aspects of heart
failure treatment that matter most to patients.
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Conclusion
We identified gaps in knowledge about heart failure treatment options, including
diagnosis, decision-making, surgery, post-operative maintenance and lifestyle
changes. Challenges included presenting risks and benefits for informed decision
making without frightening patients and circumventing reflection, and balancing
an emphasis on LVAD with other alternative treatment options like comfortdirected palliative and supportive care.

Keywords
Left ventricular assist device; heart failure treatment; decision aid; shared
decision-making

Background
Decision aids are paper- or electronic-based tools that help patients make
treatment choices, particularly where the optimal course of treatment is uncertain
and preferences guide the treatment selection. Decision aids help increase
patient and caregiver knowledge, decrease decisional conflict and regret, and
increase accurate risk perceptions and the match between values and choice1.
Whether and how patient decision aids (PDAs) help patients and caregivers
reach informed and preference-congruent decisions depends on their quality, as
defined by The International Patient Decision Aid Standards (IPDAS) and their
user-centeredness. While many decision aids claim to be patient-centered, few
studies document the process and “best practices” by which PDAs come to be
centered in patient and caregiver perspectives, beliefs, and value preferences2, 3.
This paper describes the development methodology of a decision aid to help
patients and caregivers evaluate options for treating end-stage heart failure,
particularly those eligible to receive a Left Ventricular Assist Device (LVAD). Our
primary goal is to describe the systematic and rigorous manner in which this aid
was developed so that clinicians considering using it in their clinical flow would
know its evidence-based foundation, and to encourage replicability by other
researchers who wish to develop decision aids for other cardiology-related
treatment options.
We consider decision aids particularly important for LVAD placement because
the decision about device placement is especially value-laden and preferencesensitive due to the complex trades-offs and burdens associated with the device4,
5
. Aside from the device’s high cost (among the most expensive interventions in
medicine, at $500,000-$1.4 million per quality-adjusted-life-year6, 7), additional
decision-making considerations include: duration and quality of life, convenience,
preservation of bodily integrity, body-image, limitations and changes in activities
of daily living and functional or exercise capacity, risk of death or other adverse
events, and impact on familial and other relationships8, 9.
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Aside from value tradeoffs, studies indicate poor patient understanding, even
while the number of LVAD implantations continues to dramatically increase10.
Recognizing these issues, the American Heart Association (AHA) emphasized
the “crucial” need for improved informed consent processes, increased shared
decision-making, and development of decision aids not tied to any particular
device company4. Other researchers, notably Witteman et al.3, have called for a
user-centered approach to decision aid development.
We responded to these calls by developing a patient-centered aid for decisionmaking about LVAD placement for advanced heart failure. Drawing from mixed
qualitative and quantitative methods across the fields of medical anthropology,
ethics and decision science, we outline a methodology for an inductive and
iterative discovery of user-centered decisional-needs.

Methods
Step 1. Identify the Theoretical Framework
The development of our decision aid is theoretically grounded in the Ottawa
Decision Support Framework (ODSF) and practically guided by IPDAS criteria for
ensuring quality, patient-centered content. The ODSF is an evidence-based, midrange theory for guiding patients to make health decisions, incorporating insights
on decision-making from general psychology11, social psychology12, decision
analysis13, decisional conflict14, social support15, 16, and economic concepts of
expectations and values17. The framework uses a three-step process to 1)
assess client and practitioner determinants of decisions to identify decision
support needs; 2) provide decision support tailored to client needs; and 3)
evaluate the decision making process and outcomes 18.
ODSF also provides a development toolkit for presenting information about the
condition, options, risks and benefits, values clarification, and optional elements
such as narratives/testimonials. Conceptually, we group the IPDAS/ODSF steps
together into 1) Formative Research (Steps 1-5, see Table 1); 2) Drafting the
PDA (Step 6); and 3) Pilot Testing/Finalizing the PDA (Steps 7-8). We present
them in this order below and in the Results.
Approval was granted by the Institutional Review Boards (February 2014) at our
own institution and partner hospital for each phase of the research undertaken
with the aim of creating a user-centered and clinically-informed decision aid to be
tested for effectiveness in clinical practice. The research, including patient and
clinician stakeholder engagement, data collection, decision aid drafting, cognitive
testing, and usability and alpha testing occurred from February 2014 to May 2015
(see Table 1). All participants, including patient stakeholders, provided voluntary
and informed consent to participate.
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Formative Research

Step 2. Convene Expert Panel
We began our research with the formation of an expert panel (Table 1, Step 2) to
help with the process of “scoping,” or describing the health condition (advanced
heart failure), stating the range of decisions to be considered, and specifying the
target audience. In addition to clinical experts, three patient experts who have
already undergone decision-making and LVAD treatment were selected as
members of our development team after recruiting via the “LVAD Recipient
Support Group” Facebook site and through the our partnering hospital’s LVAD
Support Group. Applicants were screened and selected based on: (1) the
richness of their answers to questions about why they want to participate, (2)
what they know now that they wish they knew before LVAD placement, and (3)
their level of involvement with other heart failure organizations as an indicator of
broader patient perspective. To select our patient partners, we used adapted
Patient Centered Outcomes Research Institute (PCORI) advisory-panel selection
criteria19 for scoring (i.e., experience with specific disease/health condition,
functional ties and experience with particular stakeholder/support group, and
degree to which their experience and background could improve our work) along
with diversity considerations. Convening the expert panel and patient consultants
took about one month (July 2013).
Regular bi-weekly meetings were held with core members of the expert panel,
comprised of four key clinical experts selected, including two cardiothoracic
surgeons, one heart failure cardiologist, and an ethicist specializing in transplant
ethics. Other clinicians, including surgeons, cardiologists, LVAD coordinators,
nurses, social workers and ethicists at our partnering hospitals were also
sometimes present.
Step 3. Literature Review of Decisional Needs
We conducted an extensive literature review for 5 purposes: (1) to evaluate
existing knowledge about user decisional needs; (2) to familiarize ourselves with
any available decisional support tools relevant to advanced heart failure
treatment; (3) to identify theoretical frameworks to confirm the relative quality and
utility of the ODSF; (4) to confirm the need for a decisional aid for currentgeneration LVAD treatment (e.g. Thoratec’s HeartMate II and HeartWare’s
HVAD), and (5) to review important considerations for LVAD placement,
including patient selection criteria and facets of information for a robust informed
consent process (e.g., quality of life determinants, predictive models,
psychological adjustment). We searched PubMed, PsycInfo, CINAHL databases,
the Cochrane Library and the existing IPDAS literature using terms such as
“LVAD,” “decision-aid,” “decisional needs,” “decisional support,” etc..
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Step 4. Assess User Needs
We then conducted semi-structured, in-depth qualitative interviews with patients,
caregivers, candidates, and decliners of LVAD treatment, in order assess users’
decisional needs from their own perspectives. These questionnaires are
available in the supplementary materials from other publications20, 21. We also
conducted in-depth interviews at this stage with clinicians, including cardiologists,
cardiothoracic surgeons, LVAD clinic team coordinators, and palliative and
supportive care specialists involved in shared decision-making, to better
understand patient informational and decisional needs from a clinical outlook.
Separate interview protocols were used for each interviewee type. Interview
domains across types included perceptions of options, outcomes, and
probabilities; values in decision-making; degree of decision-making difficulty and
factors contributing to difficulty; usual and preferred decision making roles;
decisional barriers and facilitators. A technique called “progressive focusing”
was used whereby interview questions were modified iteratively throughout the
process of data collection, so that question items with diminishing informational
returns were gradually replaced by questions eliciting new information from
patient narratives22.
Step 5. Collate the Clinical Evidence for Treatment Options
Information gained in steps 1-4 was crucial for understanding user-centered
preferences and clinical criteria for informed decision-making regarding treatment
option (see Results), paving the way for a robust patient- and caregiver-centered
presentation strategy. Specifically, we drew insights from a literature review that
included data from the INTERMACS registry, the largest annual repository of
statistics about LVADs gathered from participating hospitals across the U.S. and
published on a quarterly and annual basis, the source most trusted by our expert
panel. We summarized clinical evidence relevant to LVAD and alternative
treatment options by cross-referencing INTERMACS data with clinical trial
outcomes data for non-pulsatile LVAD therapy (including both Destination
Therapy and Bridge-to-Transplant) found in systematic reviews identified through
the PubMed, PsycInfo, CINAHL databases, and the Cochrane Library. We
excluded articles that do not present evidence-based practice guidelines or
original, peer-reviewed, empirical research.
We collated these outcomes data with information from the in-depth interviews
with clinicians and hospital staff used to assess user needs, and ongoing input
from our expert panel and patient consultants to cumulatively generate a list of
alternative treatment options with associated risks and benefits for inclusion in
the decision aid.
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Step 6. Drafting the PDA
Incorporating information from all phases of formative research above, we
developed a first draft of the decision aid, following IPDAS quality indicators
(Table 2) 23. These criteria provided guidance for the content, format and
evaluation of the decision tool. Working closely with an experienced design team,
we collaboratively planned the decision aid outline, including the ordering and
aesthetic considerations involved in information presentation. For example, we
considered whether patients would prefer to learn about the device itself first
before hearing other patients’ experiences or outcome statistics, etc. We also
considered layout and formatting issues, like whether the PDA should be all one
booklet or contain separate sheets or “pull-outs” with information to keep on-hand
(e.g. resources for patients, considerations for caregivers, etc.) that can easily be
updated as clinical evidence changes. During this time, we also held photo and
video shoots with patients and caregivers in their homes and in hospital settings
to generate footage and imagery of patient experiences with LVAD decisionmaking and treatment for inclusion in the decision aid and accompanying
website.
This phase also included the development of an LVAD Knowledge Scale for
inclusion in the decision aid as a tool for patients and caregivers to assess their
knowledge about LVAD therapy24. Knowledge about treatment options is
considered to be one of the primary components of a high-quality decision25 and
one of the standard set of outcomes used to assess decision aids1, 26. Questionitems for the scale were developed from questions and decisional needs that
emerged from participants and clinician recommendations about essential
components of informed decision-making for LVAD therapy. Development and
validation of the LVAD Knowledge Scale is described in another publication24.
Step 7. Alpha Testing
To test users’ perceptions and understanding of the content, relevance and
readability of the decision aid, we first conducted cognitive interviews or “think
aloud” exercises with patients, caregivers, and clinicians who were asked to give
qualitative feedback on each section of the decision aid. Changes were made
iteratively based on consensus in feedback. Next, we administered validated
quantitative questionnaires to evaluate patients’, caregivers’ and clinicians’
perceptions of the decision aid’s acceptability 27, covering aspects of each
section’s usability, likability, informative effectiveness, audience appropriateness,
format, timing, range of content, and any open-ended suggestions for
improvement from participants.
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Table 1: Development process of Deciding Together Using the IPDAS and ODSF
Frameworks
Step 1: Identify the theoretical framework 1/14
Framework: IPDAS
Objectives: To review alternative theoretical frameworks for decisional support.
Methods: Literature review.
Outcome: The Ottawa Decisional Support Framework was confirmed against competing
decisional frameworks for its high quality standards and frequency of implementation.
Step 2: Convene an expert panel 2/14
Framework: IPDAS / ODSF
Objectives: Incorporate expert insights and feedback on patient/caregiver needs, content and
format of PDA, implementation plans and feasibility
Methods: Expert consensus (face-to-face meetings)
Outcome:
(1) Four key clinical experts selected, including two cardiothoracic surgeons, one heart failure
cardiologist, and an ethicist specializing in transplant ethics (biweekly face-to-face meetings)
(2) Other clinicians, including surgeons, cardiologists, LVAD coordinators, nurses, social workers
and ethicists consulted intermittently for in-depth interviews about patient decisional needs and to
provide feedback on PDA materials (face-to-face meetings, online SurveyMonkey feedback about
acceptability)
(3) Three patient experts selected to provide feedback on personal knowledge and experiences,
and to vet PDA content and evaluate acceptability and usability (individual and face-to-face
meetings)
Step 3: Review the literature 2/14
Framework: IPDAS
Objectives:
(1) To assess existing information about LVAD patient population decisional needs
(2) To assess needs and parameters for decisional aid.
Methods: Review of decisional support literature.
Outcome: Literature revealed a lack of field-tested and clinician-reviewed decisional support tools
for LVAD candidates,
Step 4: Assess users’ needs 3-9/14
Framework: IPDAS / ODSF
Objectives:
The VAD Journal: http://dx.doi.org/10.13023/VAD.2016.01
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(1) Assess patient and caregiver decisional needs to tailor decisional support
(2) Assess clinicians’ perceptions about patient decisional needs, including content, format and
timing of PDA administration.
Methods: Individual in-depth interviews with patients, caregivers, LVAD decliners, and clinicians
Outcome:
(1) 15 LVAD candidates, 15 patients, 15 caregivers, 15 LVAD decliners and 11
clinicians involved in LVAD care were interviewed.
(2) All interviewees identified decisional and support needs, and their guiding values. Results
were analyzed thematically across participants and served as key messages/content for the PDA.
(3) Interactive paper- and computer-based formats were preferred by all interviewed subgroups.
Step 5: Collate the clinical evidence for treatment options 10-11/14
Framework: IPDAS / ODSF
Objectives: To review and provide a balanced summary of all treatment options in the PDA
Methods:
(1) Literature review of national clinical guidelines, and interviews with clinicians about
treatment alternatives.
(2) To gather clinical and statistical data on LVAD outcomes to portray in risks/benefits section of
the PDA
Outcomes:
Statistics on LVAD risks, benefits and outcomes were selected to present to our expert panel for
possible inclusion in the PDA. Clinical experts and the literature confirmed that for patients for
whom medical management no longer works, LVAD treatment, transplant, and palliative care are
the three predominant treatment options for end-stage heart failure.
Step 6: Drafting the PDA 11/14-1/15
Framework: IPDAS / ODSF
Objectives: Develop the first draft of the PDA, incorporating interview data and expert feedback
Methods:
(1) Integration of IPDAS-guided content from literature reviews, in-depth interviews, and face-toface meetings
(2) Work closely with the design team to draft a version of the PDA incorporating patient
knowledge needs and preferences, clinical relevancy and aesthetic appeal.
(3) Photo and video shoots with patients and caregivers in both home and hospital settings to
generate images and footage for the PDA.
Outcomes: A working draft was created, consisting of 7 main tabs, 6 stand-alone, interactive pullout sections, numerous photos and supplementary video for the website.
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Step 7: Alpha Testing of the PDA 1-4/15
Framework: IPDAS / ODSF
Objectives:
(1) Test for cognitive understandings of relevance and readability
(2) Test for acceptability to receive specific feedback on content, layout, usability, and readability
(3) Evaluate preliminary PDA content and format, including both the paper-based and web-based
(e.g. video) PDA content.
Methods:
(1) Interviews for cognitive testing and validated instruments for acceptability testing
(2) Iterative process of review and modification with feedback from patient experts and clinicians.
Outcomes: The PDA went through 5 iterations and consensus on a final draft was reached by the
researchers and patient/clinician experts. Cognitive testing was done with 5 patients. Acceptability
testing was done with 10 patients, 10 candidates, and 13 clinicians.
Step 8: Finalize the PDA 5/15
Framework: IPDAS
Objectives: Final integration of feedback from formative research & alpha testing to construct
final content for PDA.
Methods: Meetings with researchers and team members to consolidate feedback and make final
content and format decisions.
Outcomes: Final PDA developed and ready for clinical trial.

Results
All results from the above phases were merged to formulate the content and
format of the decision aid, following the IPDAS Collaboration Framework (Table
2). We describe results of each step outlined above in the same order below.
Formative Research
Step 2. Convene Expert Panel
Our expert panel provided intermittent feedback on the content and format of the
tool to meet informed consent standards and to integrate with standard
educational procedures and clinical workflow. Our experts highlighted
suggestions for providing a balanced presentation of LVAD versus other
treatment options (e.g. comfort-directed care), and how best to target a nonclinical audience without leaving out information important to decision-making.
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Table 2: Development of the LVAD Decision Aid Content using the International
Patient Decision Aids Standards Collaboration (IPDAS) Framework
1. IPDAS Criteria: Providing information about options
Domains: Development (content)
1.

Findings from the needs assessment helps to identify patient-relevant values and preferences
for decision-making, and clinical criteria for informed decision-making.
2. Overview information about options is presented in sections:
a. “About LVAD,” “LVAD Surgery,” and “Living with an LVAD”
b. “About Palliative and Supportive Care”
2. IPDAS Criteria: Presenting probabilities
Domains: Development (content)
1.

a.
b.
c.
d.

The “LVAD by the Numbers” section uses pictographs (best practice) to present facts and
figures regarding risks and benefits, based on expert input from clinicians. Information
includes:
Number of LVAD patients and their longevity
Likelihood of LVAD patients receiving heart transplants
Rate of complications and re-hospitalization after LVAD (30 days and 1 year)
Risks (top 5) of LVAD surgery

3. IPDAS Criteria: Clarifying and expressing values
Domains: Development (content)
1.
a.
b.
c.
d.
e.
f.
g.
h.
i.

Patient and caregiver values in decision-making are addressed in the “LVAD and Your
Values” section, helping users to clarify their values regarding:
Extension of life
Bridging to transplant
Improving heart failure symptoms and quality of life and mobility
Time to rehabilitation
Avoidance of complications like bleeding, infection and stroke
Dealing with daily lifestyle changes and maintenance
Increasing dependence on others and affecting caregiver’s lifestyle
Dealing with LVAD-related expenses
Using a worksheet, patients explicitly rate how important each factor is in their decision.

4. IPDAS Criteria: Guiding/coaching in deliberation and communication
Domains: Development (content)
1.
a.
b.
c.
d.

In line with IPDAS quality standards, the PDA includes a section on “How to Decide,”
designed to:
Encourage shared decision-making
Prepare patients and caregivers to identify their own values
Provide overview of information needed to make informed decisions
Compare options, including benefits and risks, of receiving versus declining LVAD treatment
(in “best practice” side-by-side format).
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5. IPDAS Criteria: Disclosing conflicts of interest
Domains: Development (process)
1.

Collaborators in the creation of the PDA are presented in the About this Decision Aid
document on the accompanying website lvaddecisionaid.com

6. IPDAS Criteria: Balancing the presentation of options
Domains: Development (content/format)
1.
a.
b.
c.
2.

The PDA provides balanced content by:
Elaborating definitions, risks and benefits of palliative care as an alternative
Presenting LVAD and its alternatives with equal, unbiased tone and in the same font and
format
Side by side presentation of benefits vs. risks challenges of receiving LVAD vs. not receiving
LVAD`
`
The balance of information was assessed in acceptability testing among patients, caregivers
and clinicians.

7. IPDAS Criteria: Using plain language (readability)
Domains: Development (format)
1.

The PDA used “plain language” as assessed during cognitive interviewing and acceptability
testing with patients, caregivers and clinicians.

8. IPDAS Criteria: Basing information on up to date scientific evidence
Domains: Development (content/process)
1.
2.

All clinical information was based on most recent findings about LVAD therapy as reported in
the continuously updated INTERMACS database and systematic reviews.
Survival statistics and outcomes/risk data were verified by clinical experts from our team.

9. IPDAS Criteria: Establishing effectiveness
Domains: Development (evaluation)
1. The PDA has undergone pilot alpha testing, including:
a. Cognitive Testing
b. Acceptability Testing
2. The PDA will undergo beta testing, including:
a. Randomized controlled trial of decision aid efficacy
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We met with our patient partner representatives (n=3) in scheduled meetings
every 1-2 months in which they helped to provide subjective feedback on the
relevance of decision aid content and format at each stage of the decision aid
development process. The most valuable information we learned from our patient
consultants are first-hand experiences about what they wished they had known
before deciding on LVAD implantation. Their personal narratives and suggestions
helped us to further generate and refine content for the PDA. Two out of our
three partner representatives also participated in alpha testing.
Step 3. Review the Literature
A review of the literature revealed that (1) There is little work on decision needs
of heart failure patients, and few guidelines for informed consent for LVAD
placement;28-30 (2) No patient decision aid currently exists for LVAD placement
for advanced heart failure, despite the calls of AHA; (3) Only 50% of decision
aids are field-tested;31 (4) A recent systematic review of 84 decision aids found
that only a handful have been reviewed by a clinician not involved in the
development process, even though the IPDAS Collaboration recommends
this;31(5) Clinician involvement in field-testing is a crucial but rarely completed
step in the development of decision aids.32
Step 4. Assess Users’ Needs
Results from a total of 60 in-depth interviews with patients (n=15), caregivers
(n=15), LVAD candidates (n=15) and decliners (n=15) form the centerpiece of
our understanding of user decisional needs. Patients were NYHA Class III and
IV, between 30-85 years old and capacitated, with an acceptable surgical
risk/benefit ratio for LVAD implantation and with good psychosocial support,
coping mechanisms, and financial resources, as determined by clearance from
the LVAD/transplant social worker. Our sample also reflected the gender (80%
male, 20% female) and age (45% 40-59, 45% 60-79) distribution in LVAD
placement33. Qualitative interviews were completed from March to August 2014
(5 months). A majority (n=52) of interviews was conducted by members of our
research team in private rooms of the LVAD clinic, while a minority (n=8) was
conducted over the phone based on patient preference and availability.
Interviews were audio-recorded, transcribed, and analyzed collaboratively using
the well-established method of Grounded Theory34 method of analysis in
ATLAS,ti, a computer-assisted qualitative data analysis software.
While findings from this phase of formative research are elaborated elsewhere20,
in summary they reveal a prevailing tendency to make decisions about LVAD
therapy reflexively among patients and caregivers, who largely believe that they
do not have a choice about whether to get an LVAD, given their values regarding
life extension, family and mobility. Patients and caregivers expressed a
preference for shared decision-making with their clinical team, as well as having
an informed/involved caregiver and hearing stories from other patients with the
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device when deciding. Over half of patients demonstrated lack of clarity
regarding LVAD therapy in relation to heart transplant. Decliners in particular
believed that LVAD placement would impact their ability to receive a transplant,
and expressed a strong preference for waiting to surgically intervene until they
felt sufficiently “sick enough.” Our decision aid aimed to improve on these
elements and answer the specific informational needs of patients.
Step 5. Collate the Clinical Evidence for Treatment Options
Our review provided clinical statistics for inclusion in the decision aid (see LVAD
by the Numbers tab of the decision aid) in order to provide patients and
caregivers with an accurate representation of risks and benefits of LVAD
treatment. Our clinical expert panel along with IPDAS requirements for evidence
presentation helped us to identify the core clinical evidence to include in the
decision aid.
In-depth interviews with clinicians (n=11) during the formative research phase
also provided a distinct perspective about what patients need to know from a
clinical standpoint in order to make an informed decision. These clinicians
included cardiologists (n=3), cardiothoracic surgeons (n=2), LVAD coordinators
(n=2), a hospital financial advisor (n=1), clinical social workers (n=2), and a
clinical bioethicist (n=1). These interviews highlighted the need for patients to
have realistic expectations about risks and benefits of LVAD treatment (both
short-term/immediately post-operative and longer term), to recognize the
importance of post-operative maintenance behaviors and support, and to better
understand of the role of LVAD in relation to transplant.
Step 6. Drafting the PDA
Based on these key messages from patients, our clinical expert feedback, the
IPDAS guidelines for decision aid content and presentation of information, and
the summary of clinical evidence, we drafted the decision aid using a
“storyboard,” a series of short sections comprising the preliminary informational
content of the decisional aid. All storyboards were reviewed with our clinician
experts for medical accuracy. We then worked with our design team to generate
and organize the content, including all the main decision aid components and
script (e.g., what is a LVAD, risks and benefits of LVADs, values clarification
exercise, etc.). We followed IPDAS guidelines for reaching audiences with lower
health literacy using pictographs, frequencies, and narratives.
In addition to drafting the print and online versions of the tool, we also worked
with the design team to host a photo and video shoot of selected participants
whose patient and caregiver narratives are featured in the decision aid. These
shoots aimed to showcase patients living with the device, and took place over the
course of multiple days on-site in patients’ homes and neighborhoods, as well as
at our partner hospital where patients regularly interact with their healthcare
team. The footage includes glimpses of and variation in patients’ experiences
The VAD Journal: http://dx.doi.org/10.13023/VAD.2016.01
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and challenges living with an LVAD (e.g. caring for the driveline; logistics of
cooking meals and cleaning house, achieving mobility to travel or spend time
with loved ones, etc.). Photos also illustrate many of the important steps of the
decision-making process, including talking to other clinicians and patients with
LVADs.
Step 7. Alpha Testing
Cognitive interviews were conducted with 3 patients and 2 candidates to assess
content clarity and readability of the entire decision aid. Cognitive interviewing
involves “think aloud” exercises where the patient is asked to review the
storyboards and describe in their own words the meaning of the information.
During this process, changes in wording, informational content, and format were
suggested to ensure the messages in the aid are being communicated clearly.
The decision aid was then tested for acceptability among 10 patients, 10
candidates, and 13 clinicians (Table 3). Findings from this phase of testing
indicated an overwhelmingly positive response to the decision aid, with 100% of
patients/candidates saying they would recommend the aid to other people
considering treatment options for heart failure, and 92% of clinicians saying they
would recommend the aid to patients making a decision. Likewise, 100% of
clinicians and patients/candidates agreed that the decision aid would help
patients understand more about the risks and benefits of LVAD treatment, and to
think about what aspects of heart failure treatment matter most to patients. Only
5% of patients/candidates felt that they had unanswered questions after reading
the decision aid, and 70% of patients/candidates reported learning something
new from the aid that they did not know before. Acceptability testing confirmed
that the decision aid was appropriately targeted to its intended audience and
reading level. A total of 95% of patients/candidates said they could relate to the
people portraits in the patients’ stories and photographs, and 100% said they
could easily understand the information they were presented with.
In terms of format, participants shared their preferences for print with
supplementary online delivery over other formats. With regard to distribution
timing, a majority (55%) of candidates preferred to receive the PDA when visiting
a local heart doctor before referral to an LVAD program, and only a quarter
(25%) preferred to receive it after being evaluated and offered LVAD therapy.
This phase of testing highlighted a need to further clarify and develop certain
sections (e.g. elaborate on palliative and supportive care) for a more informed
and balanced presentation of alternative treatment options. While
patients/candidates (100%) and clinicians (92%) agreed that the decision aid
covered both positive and negative aspects of LVAD treatment, a majority of
patients felt the decision aid “clearly” (50%) or “slightly” (20%) favored LVAD
treatment.
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Table 3
Combined UA Testing of DA (n=20) and Supplemental Videos (n=10):

Decision Aid (n=20)

%White
%Black
%Hispanic

Ratio
of BTT
to DT

7M:3F

70% White
30% Black
0% Hispanic

4 BTT :
6 DT

6M:4F

50% White
40% Black
10% Hispanic

N/A

5

61 years,
(56-69)

3M:2F

60% White
40% Black
0% Hispanic

2 BTT :
3 DT

5

57 years,
(45-68)

4M:1F

60% White
20% Black 20%
Hispanic

N/A

Average
Age, Range

10

59 years,
(26-79)

10

59 years,
(45-70)

LVAD
Patients
LVAD
Candidates

Subject Type

Supplemental Videos
(n=10)

Ratio Male
to Female

Number of
Participants

LVAD
Patients
LVAD
Candidates

Note: Clinician participants (n=13) are not featured in the table.

The PDA took an average of 59 minutes (~1 hour) to fully review, with 95% of
participants voluntarily reading the aid from cover to cover. A total of 75% of
patients and candidates thought the length was “about right.” The final version of
the decision aid can be found at www.lvaddecisionaid.com.
Step 8. Finalize the PDA: Plans for trial testing
The decision aid will be further tested in a multi-site randomized trial to take
place (over one year beginning June 2015) across five cardiovascular hospitals
across the country, including our main partner hospital. In addition to testing for
effects of the aid on decision-making, a crucial aspect of trial planning and
execution is to learn about the clinical work flow dynamics of other hospitals
through our research collaborations, and to gather insights about effective versus
non-effective distribution and dissemination strategies for the future. The main
outcome measures for the trial are: LVAD knowledge, clarity about transplant
status/eligibility, affective forecasting regarding life with LVAD, shared decisionmaking, decisional conflict, values clarity, preparedness for decision-making,
satisfaction with decisional process, and decision satisfaction/regret.
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Discussion
We created a decision aid that presents outcomes, risks, projected experiences,
and uncertainties about left ventricular assist device (LVAD) placement in a
balanced way to help patients make informed and value-based decisions about
placement.35 Combining IPDAS and ODSF guidelines at each stage of decision
aid development enabled us to ensure that the development of decision aid
content and format not only answers patient/caregiver questions, but is also
guided by an explicit quality-driven framework that is replicable by other
researchers seeking to develop similar decision aids.
A primary goal for decision aid development was to integrate clinical expertise
with user preferences, characteristics and values to ensure relevance and
acceptability. Therefore, we sought to appeal to a wide variety of stakeholders
(patients, caregivers, candidates, decliners) so that the tool could be broadly
acceptable and patient-centered. In line with our findings about decisional
needs, we paid special detail to clarifying how LVAD treatment affects transplant
status, along with lifestyle and technical issues, where patients have the most
informational needs. Taken together, findings from outcomes data as well as
from LVAD patients, candidates and clinicians helped us to tailor the content of
the decision aid in ways that address users’ perceptions and preferences, while
clarifying potential misconceptions about the range of available treatment options
for heart failure and educating patients about key aspects necessary for
providing informed consent or refusal for LVAD treatment.
We consulted clinical experts both inside and outside of our expert panel to
provide feedback on how best to integrate the decision aid into clinical flow.
Eliciting input from clinicians who were not involved in the development process
helped to reduce bias by providing an independent review of our decision aid, as
well as to make the aid more generalizable to other LVAD patient populations.
While over 500 patient decision aids have been developed worldwide36, a recent
systematic review of 84 decision aids26 found that only a handful have been
reviewed by a clinician not involved in the development process, despite IPDAS
recommendations.
A majority of the challenges we faced during the development process were
related to choices about information content. Our goal was to offer a balanced
presentation of risks and benefits without overwhelming patients, while at the
same time, satisfying clinical experts who requested that patients and caregivers
be presented with realistic expectations about outcomes and common
complications. Under the advice of our clinical experts, we erred on the side of
highlighting risks in order to ensure informed decision-making.
An additional challenge was maintaining a balanced presentation of information
about LVAD treatment in relation to other treatment options. Given that the
decision aid focuses on LVAD treatment, other treatment options were not as
deeply elaborated. Working closely with experts in palliative and supportive care
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helped us to maximize information about alternatives for addressing advanced
heart failure to ensure informed decision-making across a full range of treatment
choices. We also took into account perspectives from decliners of LVAD
treatment in order to acknowledge values influencing LVAD refusal. The content
of the decision aid is overall positive, but this is in keeping with patients’ and
caregivers’ perspectives, as reflected through our empirically-derived interviews.
A principal reason why we engaged in alpha-testing was to elucidate clinicians’
perspectives on how the tool could be integrated into clinical workflow. Since
many of our candidates preferred to receive the aid when visiting their outside
cardiologist, the decision aid could initially be provided at the referring
cardiologist’s office. However, a drawback in using the aid in the outside
cardiologist’s office is that he or she may lack familiarity with device placement,
perhaps introducing evidence that really is more program-specific. To offset this
potential drawback, it might be appropriate to provide the aid once the patient is
a candidate and is referred to a tertiary center, encouraging him or her to write
down questions to bring to the tertiary center, where the decision aid can be used
by a variety of professionals throughout the education or evaluation
process. Social workers could go over the caregiver support section, for instance,
and surgeons and cardiologists could go over the risk/benefit section of the aid.
Limitations
Acceptability of the tool was tested only among patients with sufficient cognitive
functioning, as evaluated by the coordinator and social worker on the clinical
team using guideposts provided in the Aid to Capacity Evaluation Tool (built by a
Toronto Bioethics group; validated and reliable). While none of these patients
were intubated or unconscious, many were still among the sickest inpatients
hospitalized. We envision the aid being used with similar patient populations, but
recognize that a wide range of cognitive functioning exists and not all patients will
be able to attend to the tool for the 59 minutes it takes the average patients to
thoroughly review it. For this reason, we purposefully built section tabs into the
design for quick reference depending on the unique needs and concerns of
patients and caregivers. To help ensure understanding in the cognitively
impaired, we have supplementary videos in case the patient is too sick or tired to
read.
Another potential concern is whether the decision aid applies to both DT and BTT
patients alike. After consulting with our expert panel, we concluded that because
these designations are not static and often change throughout a patient’s
treatment trajectory, the aid encompasses concerns for patients with either
designation.
An additional limitation is the small sample size and potential lack of
generalizability to other patient samples with different knowledge needs, though
the diversity of Houston’s patient population suggests that our findings likely
encompass a variety of LVAD patient samples across the United States37.
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Conclusion
This study demonstrates the feasibility of developing a user-centered and
clinically-informed decision aid for individuals facing the difficult decision of
whether or not to get an LVAD. With the help of our patient partners, expert
collaborators and experienced design team, we have developed an
information-rich and aesthetically appealing aid that addresses commonalities
in patient and caregiver questions and experiences in decision-making. The
framework and steps presented here are theoretically grounded and practically
generalizable to the development of other future decision aids.
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